CStone Pharmaceuticals
Status: Publicly traded
Direct answer
CStone Pharmaceuticals is publicly traded on HKSE under the ticker 2616.HK.
CStone Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and commercialization of advanced immuno-oncology and precision medicines. Its mission is to address critical unmet medical needs for cancer patients, both within China and across the globe. The company's market-ready portfolio includes Sugemalimab, a monoclonal antibody targeting programmed death ligand 1 (PD-L1);...
Can you invest in CStone Pharmaceuticals?
Yes. CStone Pharmaceuticals trades publicly on HKSE as 2616.HK.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for CStone Pharmaceuticals
Detailed equity research is provided by MarketSnap.